Loading...
Allergopharma plans to invest € 40 million in production facility
16-Dec-2013
- Germany
Advertisement
Merck broke ground on a new production facility for its Allergopharma unit in Reinbek near Hamburg. The new facility, which is estimated to cost nearly € 40 million, will be used, among other things, to expand production to serve new markets such as China. In the two-story building, which will be constructed on the current Allergopharma premises, products for the diagnosis and treatment of type 1 allergies such as hay fever or allergic asthma are to be manufactured under ultrapure, sterile conditions. Completion of the building is scheduled for 2016.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline
Europe to tackle brain disorder research by linking industry, academia - Brain disorders including addiction, depression, and schizophrenia afflict 1 billion people and are often incurable with current therapies
Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations
BioMerieux to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
KUROS Announces Encouraging phase IIa DATA WITH KUR-212 In Patients with Burns requiring Mesh Grafting
